Literature DB >> 28724665

The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages.

Yu-Min Yeh1,2, Shan-Ju Hsu3, Peng-Chan Lin1,2, Keng-Fu Hsu1,4, Pei-Ying Wu4, Wu-Chou Su2, Jang-Yang Chang2,5, Meng-Ru Shen6,4.   

Abstract

Purpose: Targeting tumor-associated macrophages with colony-stimulating factor 1 receptor (CSF-1R) inhibition reveals a strategy for cancer therapy. Here, we studied the impact of CSF1R germline genetic variant on CSF-1R signaling and the susceptibility to CSF-1R inhibitors.Experimental designs:CSF1R germline genetic variants were studied in 140 cancer patients. CSF-1R phosphorylation, endocytosis, and macrophage polarization were measured as the response to CSF-1 stimulation. Tumor-associated macrophages in surgical specimens and sensitivity to CSF-1R inhibitors were used to determine macrophage function.
Results: A CSF1R c.1085A>G genetic variant causing the change of histidine to arginine in the domain of receptor dimerization was identified as a high allele frequency in Eastern Asian population. Cancer patients with this variant allele had less M2-like tumor-associated macrophages accompanied by low VEGF expression in tumor tissues. Importantly, CSF1R genetic variant was significantly associated with disease-free survival in colorectal, endometrial, and ovarian cancer. In terms of differentiation, macrophages with CSF1R c.1085A>G genetic variant displayed a refractory response to CSF-1 stimulation and macrophage survival was sensitive to CSF-1R inhibitors with IC50 of 0.1 to 1 nmol/L range. On contrast, CSF-1 induced a prominent phosphorylation and rapid endocytosis of CSF-1R, leading to an M2-like dominant polarization in macrophages with CSF1R c.1085 genotype A_A, in which CSF-1R inhibitors of PLX3397, BLZ945, and GW2580 inhibited macrophage survival with IC50 of 10 to 100 nmol/L range.Conclusions: The CSF1R c.1085A>G genetic variant regulates tumor immunity by altering the polarization and function of macrophages. This genetic variant confers the sensitivity to CSF-1R inhibitors, implying as a biomarker in targeting CSF-1R signaling for cancer treatment. Clin Cancer Res; 23(20); 6021-30. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28724665     DOI: 10.1158/1078-0432.CCR-17-1007

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  Macrophage M2 polarization induced by exosomes from adipose-derived stem cells contributes to the exosomal proangiogenic effect on mouse ischemic hindlimb.

Authors:  Dihan Zhu; Takerra K Johnson; Yang Wang; Miracle Thomas; Ky Huynh; Qinglin Yang; Vincent C Bond; Y Eugene Chen; Dong Liu
Journal:  Stem Cell Res Ther       Date:  2020-04-22       Impact factor: 6.832

2.  Mutation of the PTCH1 gene predicts recurrence of breast cancer.

Authors:  Chih-Yang Wang; Yung-Chieh Chang; Yao-Lung Kuo; Kuo-Ting Lee; Pai-Sheng Chen; Chun Hei Antonio Cheung; Chih-Peng Chang; Nam Nhut Phan; Meng-Ru Shen; Hui-Ping Hsu
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

Review 3.  Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer.

Authors:  Chunxiao Li; Xiaofei Xu; Shuhua Wei; Ping Jiang; Lixiang Xue; Junjie Wang
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 12.469

4.  CD40 Pathway and IL-2 Expression Mediate the Differential Outcome of Colorectal Cancer Patients with Different CSF1R c.1085 Genotypes.

Authors:  Yu-Min Yeh; Peng-Chan Lin; Wu-Chou Su; Meng-Ru Shen
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

Review 5.  Modeling CSF-1 receptor deficiency diseases - how close are we?

Authors:  Violeta Chitu; Şölen Gökhan; E Richard Stanley
Journal:  FEBS J       Date:  2021-07-05       Impact factor: 5.622

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.